Regeneron Pharmaceuticals, Inc. (REGN) Investor Relations Documents

Regeneron Pharmaceuticals, Inc. (REGN) investor relations documents from the company's IR site: 5 presentations, 35 press releases; latest deck 2026-07-31. Read in-app with summaries. First-party data.

REGN July 2026 Corporate Presentation — Regeneron's Q2 2026 corporate presentation reports $4.3B in total revenue and $14.29 non-GAAP EPS, highlighting Dupixent's $6B global net sales.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-31PresentationREGN July 2026 Corporate Presentation
2026-07-31Press releaseRegeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
2026-07-30Press releaseRegeneron Reports Second Quarter 2026 Financial and Operating Results
2026-06-25Press releaseRegeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
2026-06-22Press releaseCemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis
2026-06-12PresentationAnnual Shareholder Meeting Presentation
2026-06-04Press releaseRegeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
2026-05-28Press releaseRegeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundi
2026-05-22Press releaseOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
2026-05-21Press releaseLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Pl
2026-05-18Press releaseRegeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Acros
2026-05-15Press releaseRegeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Meta
2026-04-29Press releaseRegeneron Reports First Quarter 2026 Financial and Operating Results
2026-04-28PresentationREGN April 2026 Corporate Presentation
2026-04-13Press releaseRead press release : Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children wit
2026-03-25Press releaseRead press release : Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and
2026-01-30Press releaseRead press release : Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
2026-01-02Press releaseRead press release : Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conf
2025-11-10PresentationRegeneron Roundtable: Factor XI Presentation
2025-10-29PresentationREGN October 2025 Corporate Presentation
2025-10-28Press releaseRegeneron Reports Third Quarter 2025 Financial and Operating Results
2025-09-30Press releaseRead press release : Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and
2025-08-01Press releaseRegeneron Reports Second Quarter 2025 Financial and Operating Results
2025-06-26Press releaseRead press release : Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call an
2025-04-29Press releaseRegeneron Reports First Quarter 2025 Financial and Operating Results
2025-03-25Press releaseRead press release : Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and
2025-02-04Press releaseRegeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
2024-10-31Press releaseRegeneron Reports Third Quarter 2024 Financial and Operating Results
2024-08-01Press releaseRegeneron Reports Second Quarter 2024 Financial and Operating Results
2024-05-02Press releaseRegeneron Reports First Quarter 2024 Financial and Operating Results
2024-02-02Press releaseRegeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2023-11-02Press releaseRegeneron Reports Third Quarter 2023 Financial and Operating Results
2023-08-03Press releaseRegeneron Reports Second Quarter 2023 Financial and Operating Results
2023-05-04Press releaseRegeneron Reports First Quarter 2023 Financial and Operating Results
2023-02-03Press releaseRegeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
2022-11-03Press releaseRegeneron Reports Third Quarter 2022 Financial and Operating Results
2022-08-03Press releaseRegeneron Reports Second Quarter 2022 Financial and Operating Results
2022-05-04Press releaseRegeneron Reports First Quarter 2022 Financial and Operating Results
2022-02-04Press releaseRegeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
2021-11-04Press releaseRegeneron Reports Third Quarter 2021 Financial and Operating Results

REGN overview · REGN earnings · REGN financials · REGN KPIs · REGN ownership · REGN peers · REGN filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.